Why the study?
Despite epidemiological links between COVID-19 and cardiovascular diseases, little is known about whether and how COVID-19 influences atrial fibrillation.
This review summarizes the prevalence, incidence, mechanisms, and management of atrial fibrillation in patients with COVID-19.
Answers are grounded in this paper and cite their sources.
Informs AF awareness in COVID-19; extends mechanistic understanding but leaves open evidence-based management strategies.
Coronavirus disease 2019 (COVID-19) is a novel, highly transmittable and severe strain disease, which has rapidly spread worldwide. Despite epidemiological evidence linking COVID-19 with cardiovascular diseases, little is known about whether and how COVID-19 influences atrial fibrillation (AF), the most prevalent arrhythmia in clinical practice. Here, we review the available evidence for prevalence and incidence of AF in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and discuss disease management approaches and potential treatment options for COVID-19 infected AF patients.
No takes yet. Share an insight, caveat, or question.
Gawałko et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: